BIMI International Medical Inc. (BIMI)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 1.94 Million USD | -57.58% |
| 2021 | 4.59 Million USD | 88.16% |
| 2020 | 2.44 Million USD | 1771.54% |
| 2019 | -146.14 Thousand USD | -131.81% |
| 2018 | 459.35 Thousand USD | -49.88% |
| 2017 | 916.51 Thousand USD | 516.07% |
| 2016 | 148.76 Thousand USD | -87.37% |
| 2015 | 1.17 Million USD | -20.67% |
| 2014 | 1.48 Million USD | -3.79% |
| 2013 | 1.54 Million USD | -16.38% |
| 2012 | 1.84 Million USD | -55.78% |
| 2011 | 4.17 Million USD | -38.98% |
| 2010 | 6.83 Million USD | 3.24% |
| 2009 | 6.62 Million USD | 50.59% |
| 2008 | 4.39 Million USD | 30.42% |
| 2007 | 3.37 Million USD | 133.99% |
| 2006 | 1.44 Million USD | 21114.68% |
| 2005 | -6858.00 USD | -25.05% |
| 2004 | -5484.00 USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 500.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 1.69 Million USD | 121.81% |
| 2023 Q2 | 2.88 Million USD | 70.63% |
| 2023 Q3 | 115.15 Thousand USD | -96.01% |
| 2022 Q4 | -7.75 Million USD | -589.06% |
| 2022 FY | 1.94 Million USD | -57.58% |
| 2022 Q3 | 1.58 Million USD | 235.33% |
| 2022 Q1 | 1.45 Million USD | 14219.78% |
| 2022 Q2 | 472.57 Thousand USD | -67.6% |
| 2021 Q2 | 1.96 Million USD | 231.75% |
| 2021 Q1 | 592.26 Thousand USD | -56.65% |
| 2021 FY | 4.59 Million USD | 88.16% |
| 2021 Q3 | 2.02 Million USD | 3.27% |
| 2021 Q4 | 10.18 Thousand USD | -99.5% |
| 2020 Q1 | -34.88 Thousand USD | 97.09% |
| 2020 Q3 | 257.27 Thousand USD | -69.69% |
| 2020 Q4 | 1.36 Million USD | 431.07% |
| 2020 FY | 2.44 Million USD | 1771.54% |
| 2020 Q2 | 848.89 Thousand USD | 2533.47% |
| 2019 Q1 | 148.03 Thousand USD | 1599.4% |
| 2019 FY | -146.14 Thousand USD | -131.81% |
| 2019 Q4 | -1.19 Million USD | -1551.12% |
| 2019 Q3 | -72.61 Thousand USD | -600.15% |
| 2019 Q2 | 14.51 Thousand USD | -90.19% |
| 2018 FY | 459.35 Thousand USD | -49.88% |
| 2018 Q1 | 31.43 Thousand USD | -93.09% |
| 2018 Q2 | 291.79 Thousand USD | 828.18% |
| 2018 Q3 | 145.99 Thousand USD | -49.96% |
| 2018 Q4 | -9873.00 USD | -106.76% |
| 2017 FY | 916.51 Thousand USD | 516.07% |
| 2017 Q2 | 293.83 Thousand USD | 133.6% |
| 2017 Q1 | 125.78 Thousand USD | -67.07% |
| 2017 Q3 | 41.94 Thousand USD | -85.72% |
| 2017 Q4 | 454.95 Thousand USD | 984.54% |
| 2016 Q2 | 57.66 Thousand USD | 138.92% |
| 2016 FY | 148.76 Thousand USD | -87.37% |
| 2016 Q1 | -148.17 Thousand USD | -186.56% |
| 2016 Q4 | 381.94 Thousand USD | 367.72% |
| 2016 Q3 | -142.66 Thousand USD | -347.39% |
| 2015 Q1 | 286.54 Thousand USD | 227.76% |
| 2015 Q3 | 373.12 Thousand USD | 7.64% |
| 2015 FY | 1.17 Million USD | -20.67% |
| 2015 Q4 | 171.18 Thousand USD | -54.12% |
| 2015 Q2 | 346.63 Thousand USD | 20.97% |
| 2014 Q1 | 405.76 Thousand USD | 45.55% |
| 2014 FY | 1.48 Million USD | -3.79% |
| 2014 Q2 | 105.07 Thousand USD | -74.1% |
| 2014 Q4 | 87.42 Thousand USD | -90.13% |
| 2014 Q3 | 886.03 Thousand USD | 743.25% |
| 2013 Q2 | 430.92 Thousand USD | 4.85% |
| 2013 Q3 | 422.11 Thousand USD | -2.05% |
| 2013 Q4 | 278.78 Thousand USD | -33.96% |
| 2013 Q1 | 410.97 Thousand USD | -33.12% |
| 2013 FY | 1.54 Million USD | -16.38% |
| 2012 Q3 | 300.24 Thousand USD | -41.1% |
| 2012 FY | 1.84 Million USD | -55.78% |
| 2012 Q4 | 614.53 Thousand USD | 104.68% |
| 2012 Q1 | 420.53 Thousand USD | -76.0% |
| 2012 Q2 | 509.75 Thousand USD | 21.22% |
| 2011 Q3 | 497.55 Thousand USD | -55.67% |
| 2011 Q1 | 799.48 Thousand USD | -37.82% |
| 2011 FY | 4.17 Million USD | -38.98% |
| 2011 Q4 | 1.75 Million USD | 252.24% |
| 2011 Q2 | 1.12 Million USD | 40.4% |
| 2010 FY | 6.83 Million USD | 3.24% |
| 2010 Q1 | 679.45 Thousand USD | -60.06% |
| 2010 Q2 | 2.02 Million USD | 197.78% |
| 2010 Q3 | 2.84 Million USD | 40.83% |
| 2010 Q4 | 1.28 Million USD | -54.88% |
| 2009 Q1 | 679.46 Thousand USD | -41.11% |
| 2009 Q2 | 1.52 Million USD | 124.41% |
| 2009 Q3 | 2.71 Million USD | 78.26% |
| 2009 Q4 | 1.7 Million USD | -37.42% |
| 2009 FY | 6.62 Million USD | 50.59% |
| 2008 Q1 | 755.52 Thousand USD | -17.67% |
| 2008 Q4 | 1.15 Million USD | -6.67% |
| 2008 Q3 | 1.23 Million USD | -1.18% |
| 2008 Q2 | 1.25 Million USD | 65.58% |
| 2008 FY | 4.39 Million USD | 30.42% |
| 2007 Q4 | 917.72 Thousand USD | 26.49% |
| 2007 Q2 | 1.5 Million USD | 568.31% |
| 2007 Q1 | 225.03 Thousand USD | 0.0% |
| 2007 FY | 3.37 Million USD | 133.99% |
| 2007 Q3 | 725.55 Thousand USD | -51.76% |
| 2006 Q2 | 2.01 Million USD | 8669.7% |
| 2006 Q3 | 1.93 Million USD | -4.25% |
| 2006 Q4 | - USD | -100.0% |
| 2006 FY | 1.44 Million USD | 21114.68% |
| 2006 Q1 | 23 Thousand USD | 435.37% |
| 2005 Q4 | -6858.00 USD | -290.32% |
| 2005 FY | -6858.00 USD | -25.05% |
| 2005 Q3 | -1757.00 USD | -12.13% |
| 2005 Q1 | -1371.00 USD | 75.0% |
| 2005 Q2 | -1567.00 USD | -14.3% |
| 2004 Q3 | -1757.00 USD | 0.0% |
| 2004 Q1 | -1757.00 USD | 100.0% |
| 2004 Q2 | -1757.00 USD | 0.0% |
| 2004 FY | -5484.00 USD | 0.0% |
| 2004 Q4 | -5484.00 USD | -212.12% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | -5.02 Billion USD | -366662993.8% |
| 2003 Q3 | -1371.00 USD | 43.37% |
| 2003 Q1 | -48.98 Thousand USD | 0.0% |
| 2003 Q2 | -2421.00 USD | 95.06% |
| 2002 Q2 | 100.62 Thousand USD | 200.5% |
| 2002 FY | 500.00 USD | 0.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q1 | -100.12 Thousand USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -105.67 Thousand USD | 1945.233% |
| China Jo-Jo Drugstores, Inc. | 31.1 Million USD | 93.732% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 90.55 Million USD | 97.847% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 90.55 Million USD | 97.847% |
| Leafly Holdings, Inc. | 37.45 Million USD | 94.793% |
| Leafly Holdings, Inc. | 37.45 Million USD | 94.793% |
| LifeMD, Inc. | 126.01 Million USD | 98.453% |
| LifeMD, Inc. | 126.01 Million USD | 98.453% |
| TRxADE HEALTH, Inc. | 2.59 Million USD | 24.952% |
| PetMed Express, Inc. | 78.64 Million USD | 97.521% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.993% |